18-MC reduces methamphetamine and nicotine self-administration in rats.
In previous studies, 18-methoxycoronaridine (18-MC), a novel iboga alkaloid congener, has been found to decrease the intravenous self-administration of morphine and cocaine in rats. In the present study, 18-MC (1-40 mg/kg, i.p.) dose-dependently decreased the i.v. self-administration of methamphetamine and nicotine. As in the previous studies, drug self-administration was reduced for > or = 24 h after the highest dose of 18-MC. A comparison of 18-MC's interactions with all four drugs of abuse studied so far indicated that 18-MC is least effective in decreasing methamphetamine self-administration and most potent in decreasing nicotine self-administration. The results suggest that a nicotinic antagonist action of 18-MC contributes to its putative anti-addictive efficacy.
Glick
S D
SD
Center for Neuropharmacology and Neuroscience, Albany Medical College, NY 12208, USA.
Maisonneuve
I M
IM
Dickinson
H A
HA
D000818:Animals; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007050:Ibogaine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008694:Methamphetamine / Q000008:administration & dosage*; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D051381:Rats; D012646:Self Administration
D000697:Central Nervous System Stimulants; D018722:Nicotinic Agonists; D007050:Ibogaine; D008694:Methamphetamine; D009538:Nicotine; C103345:18-methoxycoronaridine